SDC1 and neoplasm: Indeed, the synergistic anti-tumor effect of the combination of 4-hydroxysalicylanilide (targeting RRM2) together with the proteasome inhibitor Bortezomib has been shown in multiple myeloma cell lines, including primary CD138+ cells from Bortezomib-refractory patients [71].